Özet:

Aim: Chronic spontaneous urticaria (CSU) is characterized by recurrent urticaria, angioedema and a combination of both over a period of more than 6 weeks. Anti-immunoglobulin E (IgE) monoclonal antibody (omalizumab) treatment is an effective and safe treatment modality that can be applied in antihistamine-resistant cases in patients with CSU and the urticaria control test is a simple and useful test that evaluates the control level of the disease over the past 4 weeks.Material and Methods: Following appropriate urticaria control tests, 82 test results of 41 patients with CSU (23 females, 18 males) who received subcutaneous anti-IgE treatment at a dose of 300 mg/4 weeks for 6 months were evaluated retrospectively.Results: With each question, there was a statistically significant difference between the mean scores before treatment and at 6 months of treatment (p: 0.001 for question 1, p: 0.001 for question 2, p: 0.001 for question 3, p: 0.001 for question 4). As a result, 95.1% of the patients included in the study achieved a complete and/or partial response to treatment.Conclusion: Omalizumab treatment in patients with chronic spontaneous urticaria (CSU), is an effective and safe treatment modality, independent of the patients’ serum IgE levels, eosinophil counts, thyroid-stimulating hormone levels, C-reactive protein and sedimentation rates, presence or absence of anti-nuclear antibody (ANA) and regardless of whether angioedema is associated with chronic spontaneous urticaria. Furthermore, the urticaria control test is a practical test that can be used to evaluate the efficiency of treatment in CSU patients Downloads Download data is not yet available. Article Details How to Cite Aytekin, G., Colkesen, F., Yildiz, E., & Arslan, S. (2021). Evaluation of the effectiveness of anti-IgE treatment in patients with chronic urticaria with an urticarial control test . Annals of Medical Research, 26(11), 2619–2624. Retrieved from https://annalsmedres.org/index.php/aomr/article/view/1839 More Citation Formats ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver Download Citation Endnote/Zotero/Mendeley (RIS) BibTeX Issue Volume 26 Issue 11 (2019): November Section Original Articles CC Attribution-NonCommercial-NoDerivatives 4.0

Anahtar Kelimeler: